20.5 Treatment of Psychological Disorders

Treatment of Psychological Disorders on the PA-CAT

Quick Answer: The PA-CAT Bulletin of Information, rev. 20240815 expects familiarity with the major psychotherapy modalities—CBT, psychodynamic, humanistic, behavioral—and biomedical treatments (pharmacotherapy, ECT). You should match modality to disorder, identify mechanism, and recognize the central role of the therapeutic alliance.

Psychotherapies

Cognitive Behavioral Therapy (CBT)

CBT, developed from Beck and Ellis, is a structured, time-limited, present-focused therapy targeting the cognitive triad (thoughts about self, world, future) and maladaptive schemas. The premise: thoughts influence feelings and behavior; changing distorted cognitions changes emotion.

Common cognitive distortions include all-or-nothing thinking, catastrophizing, mind-reading, and overgeneralization. Behavioral activation is a core depression technique; exposure and response prevention is first-line for OCD; cognitive processing therapy and prolonged exposure are evidence-based for PTSD.

CBT has the strongest evidence base for anxiety disorders, major depression, and PTSD and is a high-yield PA-CAT answer for time-limited, skills-based therapy.

Psychodynamic Therapy

Psychodynamic therapy, rooted in Freud and later object relations, explores unconscious conflicts, defense mechanisms, transference, and early relationships. Free association and dream analysis are classic techniques. Modern brief psychodynamic therapy is time-limited (≈20 sessions) and focuses on a focal conflict.

Humanistic Therapy

Humanistic therapy, exemplified by Carl Rogers' client-centered therapy, emphasizes the client's innate growth potential. Core conditions are empathy, unconditional positive regard, and congruence (genuineness). Abraham Maslow's hierarchy of needs provides the motivational framework (physiological → safety → belonging → esteem → self-actualization).

Behavioral Therapy

Behavioral therapies apply learning principles directly, without focusing on cognitions:

Biomedical Therapies

Pharmacotherapy

Electroconvulsive Therapy (ECT)

ECT induces a brief therapeutic seizure under general anesthesia and muscle relaxant. It is highly effective for severe refractory depression, catatonia, and acute mania, with rapid onset (days). Common adverse effects are transient confusion and retrograde amnesia. Modern ECT is not the punitive procedure depicted in historical accounts.

Other Somatic Therapies

Transcranial magnetic stimulation (TMS) is a non-invasive depression treatment for patients not responding to medication. Deep brain stimulation (DBS) is experimental for refractory depression and OCD. Psychosurgery (anterior cingulotomy) is rare and reserved for severe refractory cases.

Evidence-Based Practice and Therapist Factors

Evidence-based practice (EBP) integrates (1) the best available research evidence, (2) clinical expertise, and (3) patient values and preferences. Empirically supported treatments are therapies with demonstrated efficacy in controlled trials for specific disorders.

The therapeutic alliance—the collaborative bond and agreement on goals/tasks—is a robust predictor of outcome across all modalities. Common factors (empathy, expectations, therapeutic relationship) often explain more variance than specific technique differences.

Matching Treatment to Disorder

This aligns with the PA-CAT Bulletin of Information, rev. 20240815 behavioral competency expectation that PAs recognize evidence-based behavioral treatments and collaborate with mental health professionals.

Therapy Modalities and Psychopharmacology Mechanisms

The PA-CAT expects you to match a psychotherapy modality to its mechanism, not just its name. Cognitive Behavioral Therapy (CBT), built on Beck and Ellis, works through cognitive restructuring (challenging distorted thoughts such as catastrophizing, all-or-nothing thinking, and mind-reading) paired with behavioral activation (scheduling rewarding activities to break the withdrawal-depression cycle). CBT is first-line for major depressive disorder, generalized anxiety disorder, panic disorder, and PTSD because it is structured, time-limited (typically 12 to 20 sessions), and skills-based. Exposure therapy operates through extinction learning: repeated, graded contact with a feared stimulus without the expected harm progressively weakens the fear response and creates new safety memories. Variants include systematic desensitization (paired with relaxation, for phobias), exposure and response prevention (for OCD), and prolonged exposure (for PTSD). Dialectical Behavior Therapy (DBT), developed by Marsha Linehan for borderline personality disorder, combines CBT skills with acceptance and mindfulness across four modules: distress tolerance, emotion regulation, interpersonal effectiveness, and mindfulness. Motivational interviewing (Miller and Rollnick), built on the Transtheoretical Model stages of change, uses OARS skills (open-ended questions, affirmations, reflective listening, summaries) to resolve ambivalence and is evidence-based for substance use and adherence problems.

Psychopharmacology items test mechanism and first-line use, so link each class to its receptor action. SSRIs (fluoxetine, sertraline) block the serotonin transporter, raising synaptic serotonin; they are first-line for depression and anxiety with a delayed onset of 2 to 6 weeks. Benzodiazepines are positive allosteric modulators at the GABA-A receptor, increasing chloride influx and hyperpolarizing neurons; they work within minutes for acute anxiety but carry tolerance, dependence, and withdrawal risk, so they are reserved for short-term use. Typical antipsychotics (haloperidol) block D2 receptors strongly, treating positive symptoms of schizophrenia (hallucinations, delusions) but carrying high extrapyramidal side effect risk. Atypical antipsychotics (risperidone, quetiapine) block D2 plus 5-HT2A receptors, covering positive and some negative symptoms with lower extrapyramidal risk but metabolic side effects. Lithium, which modulates second messengers including inositol signaling, is first-line for bipolar I disorder and uniquely reduces suicide risk.

The biopsychosocial model frames every treatment plan: biological factors (genetics, neurotransmitters), psychological factors (cognitions, coping), and social factors (support, stressors) each contribute to onset and recovery. The clinical implication the PA-CAT tests is combined treatment outperforms either alone for moderate-to-severe depression, chronic anxiety, and psychotic disorders. A depressed patient with mild symptoms may respond to CBT or an SSRI alone; one with severe, recurrent MDD typically needs both. For schizophrenia, antipsychotic medication controls positive symptoms while CBT for psychosis, family psychoeducation, and supported employment address functional recovery—medication alone rarely restores occupational and social function. When a stem describes a patient whose symptoms persist despite adequate monotherapy, the next step is usually adding the complementary modality rather than switching within the same class.